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In 2002, the British Lung Foundation published A 
smoking gun?, summarising the evidence around the 
impact of smoking cannabis on respiratory health. 
Ten years on, this report updates A smoking gun?, 
detailing the evidence published over the past decade. 
About a third of adults in the UK have tried cannabis1. An 
estimated 2.2 million used cannabis in England and Wales 
during 2010 and 2011.
Current evidence shows that smoking cannabis is 
hazardous to our lungs.  We know far less about the 
effects of cannabis smoke than the impact of tobacco 
smoke. However, there is evidence that cannabis smoke 
causes many adverse effects, including: 
• chronic coughing;
• wheezing;
• sputum (phlegm) production;
• tuberculosis;
• legionnaires’ disease;
• aspergillosis;
• acute bronchitis;
• airway obstruction;
• pneumothorax, and 
• lung cancer.
Published research shows: 
•  a link between smoking cannabis and many respiratory 
problems, including chronic coughing, sputum 
production and wheezing;
•  a connection between smoking cannabis and infective 
lung conditions such as tuberculosis (TB) and 
legionnaires’ disease 
•  a link between smoking cannabis and collapsed lung 
(pneumothorax);
•  stronger evidence than ever before that smoking 
cannabis is linked to lung cancer;
•  a lack of conclusive evidence on how smoking just 
cannabis (i.e., without tobacco) affects lung function and 
the development of chronic obstructive pulmonary 
disease (COPD), and
•  smoking both tobacco and cannabis appears to lead to 
a greater risk of COPD and pneumothorax than smoking 
a similar amount of tobacco alone. 
We believe more investment is urgently needed to find 
out the true effects of smoking cannabis on respiratory 
health. We especially need to know more about the 
impact smoking cannabis has on lung function and 
COPD risk. 
We need to dedicate more resources to raising awareness 
of the impacts of cannabis smoking on respiratory health 
(and its impact on other aspects of people’s health), 
and to supporting people who want to stop smoking 
cannabis. 
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1.1 About the report
In 2002, the British Lung Foundation published its A 
smoking gun? report summarising the impact of smoking 
cannabis on respiratory health. The report reviewed the 
evidence available at the time, which suggested that:
•  Cannabis smokers are more likely to suffer chronic 
and acute respiratory problems compared with non-
smokers.
•  Smoking cannabis damages the immune system. 
•  The cannabis smoked today is stronger than it was in  
the 1960s.
However, the report also emphasised the lack of research 
in this field and stressed the need for more research to 
increase our understanding of this complex public health 
concern.
In the decade since the publication of the original A 
Smoking Gun?, further research has started to reveal 
important new information about the effects of smoking 
cannabis on lung health. This report gives an overview of 
the current evidence.
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Who smokes cannabis in the UK?
Around a third of adults in the UK have tried cannabis. 
Latest available figures, taken from the 2010/2011 British 
Crime Survey of England and Wales, suggest that 30.7 per 
cent of 16- to 59-year-olds have used cannabis in their 
lifetime. That figure rises to 34.5 per cent for 16- to 24- 
year-olds1. 
Cannabis was the most commonly used illegal drug 
among 16- to 59-year-olds in 2010-2011; one in 15 
people said they had used it in the last year1. That’s 
around 2.2 million people in England and Wales.
Among young people, cannabis is still the most 
commonly used illicit drug. The same survey estimates 
that around one in six (17.1 per cent of ) 16- to 24-year-
olds used cannabis during 2010-20111. This is around 1.1 
million young people in England and Wales.
The Scottish Schools Adolescent Lifestyle and Substance 
Use Survey 20102 asked 37,307 Scottish 13- and 15-year-
olds about their cannabis use. It found that cannabis was 
by far the most common drug they used. Overall, 10 per 
cent of 15-year-olds and 2 per cent of 13-year-olds said 
they had used cannabis in the last month. By gender, 13 
per cent of 15-year-old boys, 8 per cent of 15-year-old 
girls, 2 per cent of 13-year-old boys, and 1 per cent of 
13-year-old girls had used cannabis in the last month.
The Drug Use in Ireland and Northern Ireland Survey 
(Drug Prevalence Survey)3 asked 2,535 15- to  64-year-
olds about their use of illicit substances during late 
2010 and early 2011. It found that cannabis was the 
most commonly used illegal drug; 24 per cent said they 
had used it. One in 20 respondents said they had used 
cannabis in the last year and 3 per cent said they had 
used it in the last month.
Despite the drug’s widespread use, public awareness of 
the health consequences of smoking cannabis remains 
low. Research conducted by TNS on behalf of the British 
Lung Foundation in May 2012 showed that almost a 
third (32 per cent) of the British population don’t think 
smoking cannabis is harmful to your health. The figure 
rises to almost 40 per cent among those aged under 
35. This contrasts with public perception of other well-
known health risks. Almost 90 per cent of the 1,045 
people surveyed recognise the negative health impact 
of smoking tobacco, and nearly 80 per cent recognise 
the health consequences of eating fatty foods – both 
areas that have been the subject of major public health 
campaigns in recent years. 
The research also revealed that 88 per cent of people 
think a typical tobacco cigarette puts you at greater risk of 
developing lung cancer than a typical cannabis cigarette. 
This stands in stark contrast to evidence, discussed later 
in this report, showing that a typical cannabis cigarette 
increases the smoker’s risk of developing lung cancer by 
20 times the amount of one tobacco cigarette.
2.2 Types and potency of cannabis used in 
the UK
There are three main species of cannabis; cannabis sativa, 
cannabis indica and cannabis ruderalis. The plant is also 
known as hemp and it has historically been used in 
making rope and other fabrics.
As an illicit drug, you can get cannabis in several forms:
•  As marijuana, also known as herbal cannabis. Marijuana 
is made up of the plant’s dried leaves and female flower 
heads. ‘Sinsemilla’ (literally ‘without seeds’) is a highly 
potent, intensively cultivated version of domestically 
grown marijuana.
•  As hashish, also known as cannabis resin. Hashish 
is made up of the resin the leaves and flower heads 
secrete, and often compressed into blocks. Cannabis 
resin can be mixed with other substances to increase its 
weight, thereby increasing profits. 
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For many years, herbal cannabis was imported into 
the UK from the Caribbean, west and north Africa and 
Asia. UK production of herbal cannabis started around 
1990. This sinsemilla is grown indoors from seeds or by 
propagating female plant cuttings, using artificial light, 
heat and control of day-length. It consists mostly of the 
flowering tops of female plants and is easy to distinguish 
from imported cannabis. 
The potency of cannabis is measured according to its 
concentration of tetrahydrocannabinol (THC). THC is 
the main component responsible for the psychoactive 
properties of the plant, including its mood-altering effects 
or ‘high’. There is THC in different concentrations in the 
stalks, leaves, flowers and seeds of the plant as well as in 
the resin secreted by the female plant. 
Sophisticated cultivation of sinsemilla has made cannabis 
stronger over the last 30 years. The average cannabis 
cigarette in the 1960s and 1970s had about 10mg of THC. 
Today, it could have up to 150mg, or 300mg if it’s laced with 
hashish oil4. That means today’s cannabis smoker is likely 
to be exposed to greater doses of THC than in the 1960s 
and 1970s5, 6 so the conclusions of many previous studies 
investigating the long-term effects of smoking cannabis 
may not be applicable to current cannabis smokers.
Data suggests the percentage of THC in sinsemilla 
increased from 5.8 per cent in 1995 to 10.4 per cent in 
20077. However, the same data suggests that the strength 
of traditional imported herbal cannabis and cannabis 
resin has varied over this time, and there appears to be no 
significant trend in potency – as might be expected, since 
the substance is often adulterated. Additionally, data from 
2008 suggests the average potency of sinsemilla was 16.2 
per cent8.
Interestingly, the type of cannabis people in the UK 
use appears to be changing. Herbal cannabis use has 
increased markedly in recent years. In 2002, it was 
estimated that around 30 per cent of the cannabis seized 
by police was herbal cannabis. But by 2008, 80.8 per cent 
of cannabis seized was herbal cannabis and 15.3 per cent 
was cannabis resin8. The remaining 3.9 per cent either 
couldn’t be identified or wasn’t cannabis. Of the herbal 
cannabis, microscopic examination of around two-thirds 
of samples showed that more than 97 per cent had been 
grown using intensive methods (sinsemilla)8. This shows 
that highly potent forms of cannabis are becoming more 
prevalent in the UK.
2.3 Active constituents of cannabis
All forms of cannabis contain more than 400 chemicals, 
including 60 different ‘cannabinoids’ - plant derivatives 
that are unique to cannabis. The most common is 
THC. THC is highly soluble in fats and rapidly absorbed 
by the lungs and gut tract lining, where it enters the 
bloodstream. From there, it travels to the heart and brain. 
Other cannabinoids include cannabidiol (CBD) and 
cannabinol. The amounts and proportions of the 
cannabinoids in each plant vary from strain to strain, and 
can be adjusted by breeding.
The intensity of cannabis’s intoxicating effects depends 
on the way it’s taken. Cannabis can be smoked, for 
example in a cannabis cigarette (‘joint’), pipe or using 
a vaporiser. There are many more complex methods of 
smoking cannabis too. Cannabis can also be swallowed 
as a food or drink. 
The concentration of THC in the blood of someone who 
has smoked cannabis is about 70-75 per cent higher 
than that of someone who has swallowed it 9. A smoker 
will inhale about half the THC in the ‘mainstream’ smoke 
of a herbal cannabis cigarette (from the mouth end, 
rather than ‘sidestream’ smoke from the burning end). It 
will quickly enter the bloodstream and reach the brain in 
minutes.
2.4 Components of cannabis smoke 
Cannabis smoke contains various chemicals, including 
THC, carbon monoxide and carcinogens (substances that 
cause cancer)10. 
Previous studies have shown that with each puff, 
the components of cannabis smoke become more 
concentrated, meaning the joint gets stronger and 
stronger towards the end11. So, smoking fewer cannabis 
cigarettes down to a shorter butt length could mean 
taking in a greater number of smoke components than 
smoking the same amount of cannabis in more cigarettes 
smoked to a longer butt length11. 
2.5 Cannabis and tobacco cigarettes
Evidence firmly shows that smoking tobacco causes 
lung cancer and chronic obstructive pulmonary disease 
(COPD). People often mix cannabis with tobacco, 
particularly resin as it needs tobacco for the desired 
‘slow burn’. This makes it difficult to isolate which health 
problems cannabis causes and which problems are 
caused by tobacco. 
The active ingredients of cannabis plants and tobacco 
plants differ. Only cannabis has THC and only tobacco 
has nicotine. Otherwise, cannabis and tobacco smoke 
contain largely the same substances12-14, including carbon 
monoxide, tar and carcinogens.
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Cannabis smoke has the same carcinogens as tobacco 
smoke, including ‘benzanthracenes’ and ‘benzpyrenes’. But 
cannabis smoke may contain up to 50 per cent higher 
concentrations than tobacco smoke15-18. 
People generally smoke cannabis cigarettes less often 
than tobacco cigarettes. However, the way they inhale 
is very different. When smoking cannabis, people take 
in a puff volume (the amount taken into the mouth) 
two-thirds larger than if they were smoking tobacco. The 
inhaled volume (the amount that reaches the lungs) is 
larger too. Cannabis smokers also hold the smoke in their 
mouths four times longer, and end up with five times 
the amount of carboxyhaemoglobin in their blood per 
cigarette smoked19.
This means it’s likely that the body retains much 
more of the products of cannabis smoke, leading to a 
greater respiratory burden of carbon monoxide and 
smoke particles than when smoking a similar quantity 
of tobacco. It’s  estimated that someone smoking a 
cannabis cigarette inhales four times more tar compared 
with smoking a tobacco cigarette. They also retain one-
third more tar in the respiratory tract20. It’s believed 
that this is because of the longer breath-holding time 
associated with cannabis, and differences in the filtering 
characteristics between the two types of cigarette.
NHS Quit Smoking teams that use carbon monoxide 
monitoring recognise that the high levels of exhaled 
carbon monoxide from inhaling cannabis are a useful 
indicator of cannabis smoking (personal communication, 
Whittington Health Quit Smoking Team, London).
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3.1 Chronic obstructive pulmonary disease 
(COPD) and lung function
The constituents of cannabis smoke are similar to those 
of tobacco smoke. The exception is that THC is found 
only in cannabis, and nicotine only in tobacco. Given 
these similarities, there is concern that regularly smoking 
cannabis could have similar health risks as regular 
tobacco smoking. 
One of the biggest risks of long-term tobacco smoking 
is developing chronic obstructive pulmonary disease 
(COPD), a term describing a number of conditions 
including emphysema and chronic bronchitis. COPD 
leads to damaged airways in the lungs, causing them to 
narrow and making it harder for air to get in and out of 
the lungs. 
As COPD is a risk in long-term tobacco smokers, it’s 
possible that cannabis smokers are also at risk of 
developing the condition. Previous studies have shown 
that cannabis smoking leads to a range of general 
respiratory problems that are consistent with a variety 
of lung conditions, including COPD. These include 
chronic cough, sputum production,  wheezing and acute 
bronchitis21-23.
To confirm a diagnosis of COPD it is crucial to take 
physiological measurements of lung function using a 
test known as ‘spirometry’. Reporting lung function data  
recorded by spirometry can give us important insights 
into the impact of cannabis smoking on lung disease, 
including COPD.
A study by Aldington et al. in 2007 looked at tobacco and 
cannabis smoking among 339 people in New Zealand24. 
Results suggested that the main effects of cannabis on 
respiratory health are wheezing, cough, chest tightness 
and sputum production. Researchers also found evidence 
linking cannabis to large airways obstruction, but not 
emphysema. The most important finding was that 
one joint of cannabis caused the same level of airflow 
obstruction as 2.5 to five tobacco cigarettes. The authors 
say this is of major public health significance24.
In addition, preliminary data presented by Reid et al.25 at 
the 2011 British Thoracic Society Winter Meeting shows 
that cannabis smokers in a north Edinburgh population 
have more respiratory problems than those who smoke 
tobacco only, despite being younger and smoking less 
tobacco. They showed an equal prevalence of airflow 
limitation. 
In 2007, Tetrault et al. carried out a systematic review of 
34 separate published studies26 from between 1 January 
1966 and 28 October 2005, which evaluated the effect 
of smoking cannabis on lung function and respiratory 
complications. The review concluded that long-
term cannabis smoking is associated with respiratory 
symptoms including cough, phlegm production and 
wheezing. These symptoms suggest obstructive lung 
disease, but lung function measurements showed no 
significant association with airway obstruction. The 
review also suggested that short-term exposure to 
cannabis is associated with bronchodilation (opening of 
the airways). 
A study by Taylor et al27 looked at cannabis and tobacco 
smoking in more than 900 young adults born in Dunedin, 
New Zealand, in 1972-1973. Researchers studied the 
subjects at age 18, 21 and 26. They found an association 
between cumulative cannabis smoking and a decreasing 
ratio of FEV1/VC, which suggests development of airflow 
obstruction. The mean FEV1/VC among subjects who 
used cannabis on 900 occasions or more was 7.2 per cent 
lower than non-users at age 18, 2.6 per cent less at 21 and 
5 per cent less at 26. 
The authors make clear that their results show only a 
marginally significant association, but explain that this 
may be due to the relatively short amount of time they 
Lung function 
Lung function tests check different variables that 
can tell doctors more about how well a person’s 
lungs are working.
They measure:
•  how much air you can take into your lungs. This is 
compared with other people your age, height and 
sex, allowing your doctor to see if you’re in the 
normal range. This is known as your ‘vital capacity’ 
(VC). To measure it,  you fill your lungs as much as 
you can (total lung capacity) and exhale forcefully 
and fully. The volume change is known as your 
‘forced vital capacity’ (FVC);
•  how much air you can blow out of your lungs and 
how fast you can do it.  This is known as your FEV1 
(forced expiratory volume in 1 second);
•  how well your lungs deliver oxygen to your blood; 
and
• the strength of your breathing muscles.
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monitored participants (eight years). Monitoring longer-
term cannabis smoking might reveal a greater effect. 
Meanwhile, a paper published by Hancox28 drew similar 
conclusions, suggesting that smoking cannabis had a 
borderline effect on airflow obstruction. 
A new study from Pletcher and colleagues29, published 
in January 2012, looked at the effects of tobacco and 
cannabis smoking on lung function in 5,115 people in the 
US over a 20-year period. As expected, this study showed 
that both FEV1 and FVC decreased relative to increasing 
tobacco exposure. 
However, the relationship between cumulative cannabis 
exposure and lung function didn’t follow a clear pattern. 
In people whose cannabis smoking was classed as 
moderate, the authors found very small increases in FEV1 
and FVC (FEV1 increased by 13 mL/joint-year (95 per cent 
CI, 6.4 to 20; P < .001) and FVC by 20 mL/joint-year (95 per 
cent CI, 12 to 27; P < .001)).
Some research studies have found more concrete links 
between smoking cannabis and the development of 
COPD. Work from Beshay et al. in 2007 linked cannabis to 
emphysema in young smokers (17 people aged between 
19 and 43)30. The study found cannabis had an effect even 
when tobacco use was taken into account - indicating 
that the emphysema was unlikely to be down to tobacco 
smoking. 
This builds on earlier studies that showed evidence of 
obstructive lung disease in cannabis smokers21, including 
a 1987 study which showed symptoms like wheezing 
and sputum production increased in cannabis users22. 
The latter study suggested that male cannabis smokers 
suffered more detrimental effects on their lung function 
than male tobacco smokers (FEV1: FVC 90.0 and 95.2 
respectively)22.  
On the other hand, a study from 2009 presents rather 
different evidence. It looked at nearly 900 people aged 
over 40 in Vancouver. Fifty-three per cent of them had 
smoked tobacco and 46 per cent had smoked cannabis. 
The study suggested that, while smoking tobacco mixed 
with marijuana increased the risk of COPD, there was no 
conclusive evidence that smoking only marijuana led to 
increased risk of respiratory problems or COPD31. 
However, smoking a mixture of marijuana and tobacco 
was associated with a greater risk of COPD than smoking 
only tobacco (COPD odds ratio 2.74, 95 per cent CI1.66–
4.52 in tobacco-only smokers vs. odds ratio 2.90, 95 per 
cent CI 1.53–5.51 in smokers of tobacco-cannabis mix). 
This suggests that, when mixed together, cannabis and 
tobacco have a detrimental effect on lung health. Risk of 
COPD increases after 50 joints mixed with tobacco. The 
authors suggest that anti-smoking campaigns should aim 
to reduce cannabis use as well as tobacco use, and try 
especially hard to reach people who regularly use both 
marijuana and tobacco. 
An earlier study from 1980 found no evidence of 
COPD or abnormalities in the smaller airways in 
cannabis smokers32. However, this study found a mild 
yet significant narrowing of larger airways in cannabis 
smokers, which they did not detect in tobacco smokers of 
a similar age. 
Clearly, there is conflicting evidence about the effect 
smoking cannabis on its own has on lung function and 
the risk of developing COPD. 
However, there is evidence that the risk of airway 
obstruction increases with the number of joint-years of 
cannabis smoking, and of an increased risk of COPD from 
smoking cannabis with tobacco regularly.
3.2 Lung cancer 
Lung cancer develops when cells in the lungs become 
abnormal and grow out of control. Over time they 
form a clump, known as a tumour. Since lung cancer 
is largely caused by smoking tobacco, and cannabis 
smoke contains many of the same cancer-causing 
agents, investigating the relationship between lung 
cancer and smoking cannabis is vital. Indeed, previous 
laboratory studies have demonstrated the cancer-causing 
effects of cannabis smoke33. However, studies in human 
populations have yielded conflicting evidence on the 
subject: some suggest there is a link between smoking 
cannabis and lung cancer34-36 while others don’t37. It’s 
worth noting that these studies are of limited value as 
they looked at relatively small numbers of people and 
didn’t take into consideration the quantity of cannabis 
smoked or the effects of smoking a mixture of tobacco 
What is ‘moderate’ 
cannabis use? 
‘Moderate’ cannabis use is defined as up to seven 
joint-years of lifetime exposure, where smoking one 
cannabis cigarette a day for one year is one joint-
year. 
So, seven joint-years would be, for example,  
one joint a day for seven years or one joint a  
week for 49 years.
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and cannabis. In addition, some previous evidence 
suggests that THC may have anti-carcinogenic effects38-40.
Cannabis smoke has up to twice the concentration of 
cancer-causing polyaromatic hydrocarbons as tobacco 
smoke 12. In addition, people tend to inhale higher 
concentrations of cancer-causing components when 
smoking cannabis because they tend to smoke the 
cigarettes without filters41 and to a smaller butt size than 
tobacco cigarettes42. Cannabis smokers also inhale more 
deeply and hold their breath for longer19, so carcinogenic 
products deposit in the lower respiratory tract. Taken 
together, this evidence forms a legitimate rationale that 
smoking cannabis may have greater potential to cause 
lung cancer than smoking tobacco. 
A rigorous case-control study by Aldington and 
colleagues43 in 2008 made significant progress in 
showing that the link exists. The authors analysed the 
smoking habits of people diagnosed with lung cancer 
and a control group without lung cancer. Their major 
finding was that smoking cannabis increases the risk of 
developing lung cancer in young adults. The study also 
suggests that smoking one cannabis cigarette a day for 
one year increases the risk of lung cancer by 8 per cent. 
Importantly, researchers took variables including tobacco 
smoking into account when calculating this figure.
By way of comparison, the same study suggests that 
smoking one pack of tobacco cigarettes (20 cigarettes) 
a day for one year increased the risk of lung cancer by 7 
per cent. This suggests that smoking just one cannabis 
cigarette increases the risk of developing lung cancer 
by a similar amount as smoking 20 tobacco cigarettes. 
The study also concluded that 5 per cent of lung cancers 
in those aged 55 or under may be caused by smoking 
cannabis.
A study by Berthiller and colleagues looking at cannabis 
smoking in North African men showed a 2.4-fold increase 
in the risk of lung cancer among men who had smoked 
cannabis compared with those who had never smoked 
it. This was after adjustment for age, tobacco smoking, 
occupational exposures and country44.
Further research is needed to confirm these findings 
and to explain why smoking a cannabis cigarette might 
pose a greater risk than smoking a tobacco cigarette. 
Identifying the mechanisms by which the components of 
cannabis smoke may cause lung cancer is also crucial. 
3.3 Collapsed lung (pneumothorax)
Collapsed lung (pneumothorax) happens when there 
is a tear or breach in the lung, allowing air into the lung 
cavity. This makes the lungs deflate, compress and 
partially ‘collapse’. An injury from broken ribs or even 
from some medical procedures can cause this, while a 
‘spontaneous’ pneumothorax can happen without any 
warning. This leads to sudden unexpected breathlessness 
and/or chest pain, which is worse when you breathe.
Selected case reports and series have suggested that 
smoking cannabis may be associated with an increased 
risk of pneumothorax. Some evidence suggests a 
link between cannabis smoking and spontaneous 
pneumothorax30, 45-48. Some of these studies only have 
evidence from a few cases45-48. However, one study30 
found 17 young Swiss patients (16 men with an average 
age of 27) who were regular cannabis smokers and had 
suffered spontaneous pneumothorax. These patients 
didn’t have any symptoms but CT scans showed damage 
to their lungs, including multiple bullae or emphysema at 
the lung apices. The report suggests that pneumothorax 
in cannabis smokers is possibly caused by coughing while 
holding their breath as they smoke a cannabis cigarette48.
In addition, the risk of pneumothorax appears to increase 
in tobacco smokers49 and people who smoke both 
tobacco and cannabis may face a greater risk than those 
who only smoke tobacco46, 47. 
X-ray showing collapse of the left lung
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3.4 Respiratory infections and immune 
effects
There is now lots of research showing that THC stops 
the human immune system working as well as it should. 
Studies suggest that THC suppresses several cells in 
the immune system, including macrophages, natural 
killer cells and T cells50-53. Researchers are starting to 
understand more about how the components of 
cannabis smoke affect the immune system54.
Current evidence shows that cannabis smokers are more 
at risk of developing a range of infective lung conditions. 
One study55 shows that cannabis smokers are at increased 
risk of developing legionnaires’ disease. Several studies 
report cannabis smokers developing tuberculosis56-59. One 
of these56 shows how a cluster of cannabis smokers in 
Seattle, USA developed tuberculosis. 
In another study, a 34-year-old man developed 
pulmonary aspergillosis 75 days after a marrow transplant 
for chronic myelogenous leukaemia. He had been 
smoking marijuana heavily for several weeks before 
admission to hospital. Cultures grown from his marijuana 
revealed the mould aspergillus fumigates. This was 
identical to the mould grown from an open lung biopsy 
specimen, providing evidence that the marijuana caused 
the aspergillosis infection60.
Lower immune function may explain why there appears 
to be a link between cannabis use and opportunistic 
bacterial and fungal pneumonias in people with 
cancer61, transplant patients60, 62 and people with human 
immunodeficiency virus (HIV) infection63.
3.5 Broader health effects, including 
mental health and cardiovascular disease
The wider impacts of smoking cannabis are well 
documented and include dependence on the drug, 
increased risk of motor vehicle accidents, cardiovascular 
disease and mental health problems64.
Cannabis has some of the features of addictive drugs, 
including tolerance (having to take more and more to get 
the same effect) and withdrawal symptoms, including 
craving, decreased appetite, difficulty sleeping, weight 
loss, aggression, anger, irritability and restlessness. These 
cause about the same level of discomfort as withdrawing 
from tobacco. In Australia, Canada and the US, cannabis 
dependence is the most common type of drug 
dependence after alcohol and tobacco65. It is estimated 
that 9 per cent of cannabis users will become dependent 
over their lifetime66. This rises to one in six for people who 
start using cannabis in adolescence66. The equivalent risks 
are 32 per cent for nicotine, 23 per cent for heroin, 17 per 
cent for cocaine, 15 per cent for alcohol and 11 per cent 
for stimulants67.
Cannabis and THC impair68 people’s reaction times, 
information processing, perceptual–motor coordination, 
motor performance and attention68, 69, according to 
laboratory tests. The more someone smokes, the worse 
these effects will be. If cannabis users drive while they’re 
intoxicated64, it can increase the risk of having an accident 
two- or three-fold68. In comparison, alcohol makes you 
6–15 times more likely to crash. 
Research has also shown that cannabis has adverse 
effects on cardiovascular health. Cannabis use and 
isolated THC have been shown to increase heart rate. 
The more cannabis or THC a person takes, the more their 
heart rate increases64. One study showed that cannabis 
use can increase the risk of myocardial infarction (heart 
attack) by 4.8 times in the hour after someone uses it70. A 
related study reported that people who smoke cannabis 
less than once a week are more than twice as likely to 
die from a heart attack, compared with people who 
don’t use cannabis. That rises to four times more likely 
in people who use cannabis more than once a week71. 
Laboratory studies indicating that smoking cannabis 
causes angina in patients with heart disease72 support 
these findings.
Researchers have found that smoking cannabis affects 
mental health. A study of 50,465 Swedish men found that 
those who had smoked cannabis by the time they were 
18 were more than twice as likely to be diagnosed with 
schizophrenia as those who had not73. Their schizophrenia 
risk increased the more they used cannabis. The study 
also showed that people who had used cannabis 10 
times or more by the age of 18 were around twice as 
likely to be diagnosed with schizophrenia as those who 
had not. 
A related study showed that the more cannabis 18-year-
olds used, the higher their risk of schizophrenia74. The 
researchers estimated that 13 per cent of schizophrenia 
cases could be prevented if people hadn’t smoked 
cannabis. Studies in the Netherlands75, Germany76 and 
New Zealand77, 78 have supported these findings.
Cannabis has other effects on mental function too, 
according to UK mental health charity Mind. Heavy users 
can experience lethargy, loss of communication skills and 
a general lack of ambition. Cannabis is thought to affect a 
person’s ability to store new memories, but not memories 
that are already in place. In a study of adolescents in 
Australia, those who used more cannabis were more likely 
to develop depression and anxiety79. Further research 
has shown cannabis causes panic attacks and anxiety, 
depression, tiredness and low motivation in a significant 
number of users80.
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3.6 Medicinal use of cannabis
Some research suggests that cannabis may have 
legitimate medical uses81, including; to treat chronic pain, 
help AIDS patients with anorexia to eat more, prevent 
vomiting caused by cancer chemotherapy, relieve pain 
in rheumatoid arthritis and relieve pain and diarrhoea 
in Crohn’s disease81. The immunosuppressive effects of 
cannabis derivatives53 may also help treat inflammatory 
disorders82. 
Evidence from the 1970s suggests that taking cannabis 
or THC orally can open up the airways in people who 
have asthma - as well as in people who don’t have 
airways disease - for two to four hours83-85. However, 
more recent research has suggested that this short-
term ‘bronchodilator’ effect is modest and doesn’t 
appear to be sustained with continued use over 
six to eight weeks86. There are other medicines that 
have a greater effect. For example, salbutamol (the 
established bronchodilator inhaler medication) has 
greater bronchodilator effects after five minutes than 
THC86. Also, we need to weigh the potential short-term 
therapeutic effects against increasing evidence of the 
adverse effects, including increased cough, sputum  
production and wheeze, which have been associated 
with regular inhaled cannabis use86.  
Our understanding of how cannabis derivatives affect 
the body has greatly improved in recent years with 
the description of two cannabinoid receptors and 
the cannabinoid system. Evidence suggests that the 
cannabinoid system is involved in many physiological 
and pathological processes and consequently, has 
therapeutic potential81. 
Despite this, using ‘crude cannabis’ as a medicine is still 
unsanctioned. Indeed, in 2005 the UK Court of Appeal 
rejected a bid to allow the use of cannabis to relieve chronic 
pain. The negative health effects of smoking cannabis have 
been well-documented (as summarised in this report) 
and cannabinoid treatment can have side-effects81. 
We need to do a great deal of further work to develop 
safe, effective medicines. The British Medical Association 
says that crude cannabis is unsuitable for medical use 
because it contains toxic components that are harmful 
to human health. However, it would like to see more 
research into the potential for cannabis-based medicines 
to relieve pain.  
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Although cannabis is the world’s most widely used illicit 
drug, there has been surprisingly little research into its 
effects on respiratory health. Part of the problem is the 
inherent difficulty of studying the long-term effects of an 
illegal habit. 
Renewed efforts are needed to overcome  these issues 
and to get conclusive answers. Further work is also 
needed to clarify the true effects of smoking cannabis on 
several key aspects of respiratory health, including lung 
function, COPD and lung cancer. 
Given the addictive nature of cannabis, more research is 
needed into how best to support people to give it up. 
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Current evidence shows that cannabis smoking poses 
a substantial hazard to our lungs, although we know far 
less about the effects of cannabis smoke than the effects 
of tobacco smoke. There are established links between 
cannabis smoking and: 
• chronic coughing;
• wheezing;
• sputum production;
• tuberculosis;
• legionnaires’ disease;
• aspergillosis;
• airway obstruction;
• acute bronchitis;
• pneumothorax, and 
• lung cancer.
Current evidence is contradictory about the effect of 
smoking cannabis on lung function and COPD. However, 
it’s important to note that research suggests that 
smoking a mixture of tobacco and cannabis is linked to 
a greater risk of COPD than smoking a similar amount 
of tobacco alone. Evidence suggests that this is true for 
pneumothorax too. New research provides stronger 
evidence than ever before to support a link between 
cannabis smoking and lung cancer. 
 
We recommend that public health education 
programmes be implemented to dispel the myth that 
smoking cannabis is relatively safe, and to highlight the 
adverse respiratory effects of smoking cannabis mixed 
with tobacco. This position is supported by a statement 
published by the Thoracic Society of Australia and New 
Zealand in 2003. British Lung Foundation research has 
shown than almost a third (32 per cent) of people in 
Britain wrongly believe that smoking cannabis does not 
harm your health, with only 12 per cent realising that a 
typical cannabis cigarette increases the risk of lung cancer 
more than a typical tobacco cigarette. By comparison, 
eating fatty foods and smoking tobacco – two areas 
that have been the focus of public health education 
programmes in the UK – were recognised as harmful to 
health by nearly 80 per cent and 90 per cent of people 
respectively. 
People aged under 35 are most likely to have used 
cannabis but least likely to be aware that it is poses 
health risks. This suggests that public health campaigns 
should be particularly targeted towards younger people. 
To support this approach, investment in the design and 
delivery of effective cannabis smoking cessation services 
and public health education programmes is paramount, 
to maximise the success of such.
Finally, we recommend further investment in research 
targeted at providing more conclusive evidence on the 
effects of smoking cannabis on lung function, COPD and 
lung cancer. Despite being one of the most commonly 
used recreational drugs in the UK, there has been little 
investigation into the impact cannabis has on health. 
On the other hand, there has been extensive research 
into the risks associated with alcohol and tobacco. This 
has boosted our understanding of the dangers they 
pose to our health, informed Government policy and 
affected public attitudes. Similar research into cannabis is 
necessary if we are to minimise the impact it is having on 
people’s health.
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